The phase 3 trial compares trastuzumab deruxtecan (Enhertu; AstraZeneca, Daiichi Sankyo) in combination with pertuzumab (Perjeta, Genentech) vs. current first-line standard of care in patients ...

CHICAGO — Trastuzumab deruxtecan plus pertuzumab showed significant improvement in PFS compared with taxane chemotherapy plus trastuzumab and pertuzumab across patients with HER2-positive ...

ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab reduced the risk of disease progression or death by 44% vs. THP as 1st-line therapy in patients with HER2-positive metastatic breast ...

Her main takeaway was that while trastuzumab deruxtecan plus pertuzumab could be a new standard of care, questions remain—especially regarding optimal treatment sequencing and duration of therapy.

DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) received U.S. FDA approval in May 2020 and is approved for nine indications in MM, four of which are for frontline treatment in newly diagnosed ...

Topline data were announced from a phase 3 trial evaluating fam-trastuzumab deruxtecan-nxki followed by THP in patients with high-risk, locally advanced HER2-positive early stage breast cancer.

ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab demonstrated highly statistically significant and clinically meaningful improvement in progression-free survival vs. THP as 1st-line ...

Enhertu (fam-trastuzumab deruxtecan-nxki) is currently indicated as a second-line therapy for HER2-positive metastatic breast cancer.

Adrienne Waks, MD, on Subcutaneous vs IV Trastuzumab/Pertuzumab in Breast Cancer – Reduced 'time toxicity' for patients ...

Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up The following represents disclosure information provided by authors of this ...